Smith & Nephew books Q1 sales slightly better than projections
The British medtech firm and Coloplast rival, Smith & Nephew, goes up on the London stock exchange after publicizing its Q1 figures.
by marketwire, translated by daniel pedersen
Following Smith & Nephew’s first quarterly report from 2022, the company’s stock price increased 2.4 percent to GBP 12.99 on the London stock exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Smith & Nephew releases full-year report, appoints new CEO
For subscribers
Convatec expects up to 5.5 percent growth in 2022
For subscribers
